dominant-negative transforming growth factor-beta receptor type ii-expressing preferentially expressed antigen in melanoma-specific t cells

This is an adoptive cell therapy utilizing autologous T cells engineered to enhance their anti-tumor activity, particularly in solid tumors like melanoma. The T cells are modified to express a T-cell receptor (TCR) specific for Preferentially Expressed Antigen in Melanoma (PRAME), a tumor-associated antigen. Additionally, these T cells are engineered to express a dominant-negative form of the transforming growth factor-beta receptor type II (TGF-βRII). This modification renders the T cells resistant to the immunosuppressive effects of TGF-β, a cytokine abundant in the tumor microenvironment that typically inhibits T-cell function. By overcoming TGF-β-mediated immunosuppression, these engineered T cells are designed to maintain their effector functions and improve therapeutic efficacy against PRAME-expressing melanoma cells.

Other names

PRAME-specific T cells with dominant-negative TGF-βRIIdnTGF-βRII PRAME-T cells